Skip to main content

Table 1 Patient characteristics

From: Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

  Number (%) Number in those with clinical benefit (%) Number in those without clinical benefit (%) P
Gender
 Male 31 (91.2) 15 (88.2) 16 (94.1) 0.54
 Female 3 (8.8) 2 (11.8) 1 (5.9)  
Age
  < 65 22 (64.7) 11 (17.7) 11 (17.7) 1.00
  ≥ 65 12 (35.3) 6 (35.3) 6 (35.3)  
Race
 White 25 (73.6) 11 (64.7) 14 (82.4) 0.49
 Black 6 (17.7) 4 (23.5) 2 (11.8)  
 Asian 2 (5.9) 1 (5.9) 1 (5.9)  
 Hispanic 1 (2.9) 1 (5.9) 0 (0)  
Smoking history
 Yes 24 (70.6) 11 (64.7) 13 (76.5) 0.45
 No 10 (29.4) 6 (35.3) 4 (23.5)  
ECOG
 0 or 1 31 (91.2) 15 (88.2) 16 (94.1) 0.54
  ≥ 2 3 (8.8) 2 (11.8) 1 (5.9)  
Primary tumor location
 Nasopharynx 5 (14.7) 4 (23.5) 1 (5.9) 0.51
 Oral cavity 5 (14.7) 3 (17.6) 2 (11.8)  
 Oropharynx 15 (44.1) 7 (41.2) 8 (47.1)  
 Hypopharynx 1 (2.9) 0 (0) 1 (5.9)  
 Larynx 6 (17.7) 2 (11.8) 4 (23.5)  
 Sinus 2 (5.9) 1 (5.9) 1 (5.9)  
Virus association
 EBV 5 (14.7) 4 (23.5) 1 (5.9) 0.28
 HPV/p16 14 (41.2) 7 (41.2) 7 (41.2)  
 None 15 (44.1) 6 (35.3) 9 (52.9)  
Number of prior systemic therapy regimens
 0 or 1 18 (52.9) 11 (64.7) 7 (41.2) 0.17
 2 or more 16 (47.1) 6 (35.3) 10 (58.8)  
PD-1 Inhibitor
 Nivolumab 16 (47.1) 9 (52.9) 7 (41.2) 0.49
 Pembrolizumab 18 (52.9) 8 (47.1) 10 (58.8)  
  1. EBV Epstein-Barr virus, ECOG PS Eastern Cooperative Oncology Group Performance Status, HPV human papillomavirus, IO Immuno-oncology